PAVmed (NASDAQ:PAVM – Get Free Report) had its price target raised by research analysts at Ascendiant Capital Markets from $19.00 to $19.50 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.
PAVmed Price Performance
Shares of PAVM stock opened at $0.71 on Monday. The stock’s fifty day moving average price is $0.71 and its 200 day moving average price is $0.81. PAVmed has a 1-year low of $0.55 and a 1-year high of $2.43. The company has a market cap of $12.14 million, a price-to-earnings ratio of -0.16 and a beta of 1.13.
Institutional Investors Weigh In On PAVmed
An institutional investor recently raised its position in PAVmed stock. First Manhattan CO. LLC. boosted its position in shares of PAVmed Inc. (NASDAQ:PAVM – Free Report) by 16.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 700,000 shares of the company’s stock after acquiring an additional 100,000 shares during the quarter. First Manhattan CO. LLC. owned about 6.32% of PAVmed worth $439,000 at the end of the most recent reporting period. Institutional investors own 19.93% of the company’s stock.
About PAVmed
PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.
Read More
- Five stocks we like better than PAVmed
- What is Forex and How Does it Work?
- 3 Momentum Stocks That Could Soar Post-Market Volatility
- Why is the Ex-Dividend Date Significant to Investors?
- Duolingo Stock: EdTech Growth Meets Subscription Strength
- 3 Stocks to Consider Buying in October
- 3 New ETFs Finding Early Traction With Investors
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
